MiRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies

Deepak Chitkara, Anupama Mittal, Ram I Mahato

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a severe pancreatic malignancy and is predicted to victimize 1.5% of men and women during their lifetime (Cancer statistics: SEER stat fact sheet, National Cancer Institute, 2014). miRNAs have emerged as a promising prognostic, diagnostic and therapeutic tool to fight against pancreatic cancer. miRNAs could modulate gene expression by imperfect base-pairing with target mRNA and hence provide means to fine-tune multiple genes simultaneously and alter various signaling pathways associated with the disease. This exceptional miRNA feature has provided a paradigm shift from the conventional one drug one target concept to one drug multiple target theory. However, in vivo miRNA delivery is not fully realized due to challenges posed by this special class of therapeutic molecules, which involves thorough understanding of the biogenesis and physicochemical properties of miRNA and delivery carriers along with the pathophysiology of the PDAC. This review highlights the delivery strategies of miRNA modulators (mimic/inhibitor) in cancer with special emphasis on PDAC since successful delivery of miRNA in vivo constitutes the major challenge in clinical translation of this promising class of therapeutics.

Original languageEnglish (US)
Pages (from-to)34-52
Number of pages19
JournalAdvanced Drug Delivery Reviews
Volume81
DOIs
StatePublished - Jan 1 2015

Fingerprint

MicroRNAs
Pancreatic Neoplasms
Adenocarcinoma
Therapeutics
Neoplasms
National Cancer Institute (U.S.)
Base Pairing
Pharmaceutical Preparations
Gene Expression
Messenger RNA
Genes

Keywords

  • Cationic carriers
  • Chemical modifications
  • Chemoresistance
  • Desmoplasia
  • EMT
  • MiRNA

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

MiRNAs in pancreatic cancer : Therapeutic potential, delivery challenges and strategies. / Chitkara, Deepak; Mittal, Anupama; Mahato, Ram I.

In: Advanced Drug Delivery Reviews, Vol. 81, 01.01.2015, p. 34-52.

Research output: Contribution to journalReview article

@article{fb5563b3d6d748f6a8b0cac2bd1963a5,
title = "MiRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a severe pancreatic malignancy and is predicted to victimize 1.5{\%} of men and women during their lifetime (Cancer statistics: SEER stat fact sheet, National Cancer Institute, 2014). miRNAs have emerged as a promising prognostic, diagnostic and therapeutic tool to fight against pancreatic cancer. miRNAs could modulate gene expression by imperfect base-pairing with target mRNA and hence provide means to fine-tune multiple genes simultaneously and alter various signaling pathways associated with the disease. This exceptional miRNA feature has provided a paradigm shift from the conventional one drug one target concept to one drug multiple target theory. However, in vivo miRNA delivery is not fully realized due to challenges posed by this special class of therapeutic molecules, which involves thorough understanding of the biogenesis and physicochemical properties of miRNA and delivery carriers along with the pathophysiology of the PDAC. This review highlights the delivery strategies of miRNA modulators (mimic/inhibitor) in cancer with special emphasis on PDAC since successful delivery of miRNA in vivo constitutes the major challenge in clinical translation of this promising class of therapeutics.",
keywords = "Cationic carriers, Chemical modifications, Chemoresistance, Desmoplasia, EMT, MiRNA",
author = "Deepak Chitkara and Anupama Mittal and Mahato, {Ram I}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.addr.2014.09.006",
language = "English (US)",
volume = "81",
pages = "34--52",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - MiRNAs in pancreatic cancer

T2 - Therapeutic potential, delivery challenges and strategies

AU - Chitkara, Deepak

AU - Mittal, Anupama

AU - Mahato, Ram I

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a severe pancreatic malignancy and is predicted to victimize 1.5% of men and women during their lifetime (Cancer statistics: SEER stat fact sheet, National Cancer Institute, 2014). miRNAs have emerged as a promising prognostic, diagnostic and therapeutic tool to fight against pancreatic cancer. miRNAs could modulate gene expression by imperfect base-pairing with target mRNA and hence provide means to fine-tune multiple genes simultaneously and alter various signaling pathways associated with the disease. This exceptional miRNA feature has provided a paradigm shift from the conventional one drug one target concept to one drug multiple target theory. However, in vivo miRNA delivery is not fully realized due to challenges posed by this special class of therapeutic molecules, which involves thorough understanding of the biogenesis and physicochemical properties of miRNA and delivery carriers along with the pathophysiology of the PDAC. This review highlights the delivery strategies of miRNA modulators (mimic/inhibitor) in cancer with special emphasis on PDAC since successful delivery of miRNA in vivo constitutes the major challenge in clinical translation of this promising class of therapeutics.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a severe pancreatic malignancy and is predicted to victimize 1.5% of men and women during their lifetime (Cancer statistics: SEER stat fact sheet, National Cancer Institute, 2014). miRNAs have emerged as a promising prognostic, diagnostic and therapeutic tool to fight against pancreatic cancer. miRNAs could modulate gene expression by imperfect base-pairing with target mRNA and hence provide means to fine-tune multiple genes simultaneously and alter various signaling pathways associated with the disease. This exceptional miRNA feature has provided a paradigm shift from the conventional one drug one target concept to one drug multiple target theory. However, in vivo miRNA delivery is not fully realized due to challenges posed by this special class of therapeutic molecules, which involves thorough understanding of the biogenesis and physicochemical properties of miRNA and delivery carriers along with the pathophysiology of the PDAC. This review highlights the delivery strategies of miRNA modulators (mimic/inhibitor) in cancer with special emphasis on PDAC since successful delivery of miRNA in vivo constitutes the major challenge in clinical translation of this promising class of therapeutics.

KW - Cationic carriers

KW - Chemical modifications

KW - Chemoresistance

KW - Desmoplasia

KW - EMT

KW - MiRNA

UR - http://www.scopus.com/inward/record.url?scp=84922246577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922246577&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2014.09.006

DO - 10.1016/j.addr.2014.09.006

M3 - Review article

C2 - 25252098

AN - SCOPUS:84922246577

VL - 81

SP - 34

EP - 52

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -